Generic Companies Gain Little From FDA Decision On Access To REMS Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency says the FDAAA does not allow a REMS to state that a brand sponsor cannot use a limited distribution program to prevent generic drug maker’s access to a product for bioequivalence testing.
You may also be interested in...
REMS Class-Action Lawsuit Against Celgene Is First By Patients
Patients For Affordable Drugs Founder David Mitchell alleges Celgene's unlawful delay tactics like REMS obstruction kept generic versions of Thalomid and Revlimid off the market, forcing plaintiffs to pay higher costs.
REMS Class-Action Lawsuit Against Celgene Is First By Patients
Patients For Affordable Drugs Founder David Mitchell alleges Celgene's unlawful delay tactics like REMS obstruction kept generic versions of Thalomid and Revlimid off the market, forcing plaintiffs to pay higher costs.
REMS “Abuses” Concern FDA, But Can Scolding Help Speed Generic Entry?
Brand name companies’ use of restricted distribution programs to block the development of generic drugs has been an unintended consequence of the FDA Amendments Act of 2007. The generics industry has long complained that the use of FDA-required risk management plans prevents access to affordable medicines. While that battle has ranged in the courts, FDA has remained quiet on the subject. Until now.